TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$207 Million

Avidity Biosciences

Follow-on Offering

Lead Left Bookrunner, December 2022

Avidity Biosciences

Avidity Biosciences, Inc. (NASDAQ: RNA) (“Avidity” or “The Company”) is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. The Company’s proprietary AOC platform is designed to combine the specificity of monoclonal antibodies, or mAbs, with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The Company is initially focused on muscle diseases to demonstrate the capabilities of its AOCs and has three muscle programs in clinical development.